Skip to main content

Jim Cramer says Eli Lilly isn't a 'one trick pony' after FDA advisers endorse its Alzheimer's drug

CNBC's Jim Cramer on Tuesday told investors why he continues to be bullish about pharmaceutical giant Eli Lilly.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.